Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pidnarulex - Senhwa Biosciences

Next Previous
Drug Profile

Pidnarulex - Senhwa Biosciences

Alternative Names: CX-5461

Latest Information Update: 19 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer BC Cancer Research Centre; Canadian Cancer Trials Group; Peter MacCallum Cancer Centre; Senhwa Biosciences
  • Class Amides; Antineoplastics; Heterocyclic compounds with 4 or more rings; Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action G-Quadruplex modulators; RNA polymerase I inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Haematological malignancies; Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 11 Dec 2023 Peter MacCallum Cancer Centre suspended the enrollment in the phase I trial in Prostate cancer in order to further assess supplementary non-clinical study data
  • 18 Jan 2023 Senhwa Biosciences and Canadian Cancer Trials Group completes a phase I trial in Solid tumours (Late Stage) in Canada (IV) (NCT02719977)
  • 21 Oct 2022 Phase-I clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Australia (IV) (NCT05425862)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top